| Document |
Document Title |
|
WO/2021/012721A1 |
Disclosed in the present invention are a naphthalenesulfonamide compound, a preparation method, and an application. The naphthalenesulfonamide compound provided by the present invention can interfere with Keap1-Nrf2 binding and activate ...
|
|
WO/2021/016333A1 |
The present disclosure provides pharmaceutical compositions comprising aryl sulfonamide Stat3 small molecule inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use for treating cancer.
|
|
WO/2021/009566A1 |
Described herein are N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl) carbamoyl)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds of formula (I) wherein R1 is formulae (II), (III), (IV), (V), (VI), (VII), (VIII) or (...
|
|
WO/2021/011592A1 |
Scaffold compounds are used to design small molecule compounds and structure- activity relationship studies identify inhibitors of inflammation· Methods include pharmaceutical compositions of the small molecule compounds to inhibit, pre...
|
|
WO/2021/009568A1 |
Provided herein are benzenesulfonamide derivatives having Formula (III), pharmaceutical compositions comprising said compounds, and method for using said compounds for disrupting proteins/polypeptides, protein/polypeptide function, and f...
|
|
WO/2021/007663A1 |
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...
|
|
WO/2021/009567A1 |
Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2021/007478A1 |
Provided herein are sulfone compounds, for example, a compound of Formula A, or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant there...
|
|
WO/2021/003084A1 |
A compound has Formula I: (I). R1 is hydrogen, hydroxy, halogen, nitro, amino, alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkyamino, heterocyclyl, aryl, heteroaryl, -NR7R8, -CO-R10, or -NH-CO-R10; L is a bond, a heterocyclic bivalent gr...
|
|
WO/2020/261752A1 |
One problem addressed by the present invention is to provide a method for producing an active light sensitive or radiation sensitive resin composition which is capable of forming a pattern that is suppressed in defects. Another problem a...
|
|
WO/2020/254558A1 |
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC...
|
|
WO/2020/255585A1 |
The present invention provides a method for purifying a compound that generates an acid when irradiated with active light or radiation, said method being capable of reducing the content of metal impurities, while having excellent recover...
|
|
WO/2020/257037A1 |
Provided is a pharmaceutical composition comprising: (a) granules comprising dichlorphenamide, or a pharmaceutically acceptable salt thereof, and one or more intragranular excipients; and an extragranular portion comprising at least one ...
|
|
WO/2020/222675A1 |
This invention relates to an active ingredient of a pharmaceutical composition, said active ingredient being in the form of micronized crystals of monoclinic symmetry (MCMS) of sodium {[4-({[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluoroph...
|
|
WO/2020/214560A1 |
A method of producing purified bis(fluorosulfonyl) imide includes providing a liquid mixture including bis(fluorosulfonyl) imide and fluorosulfonic acid and then contacting the liquid mixture with gaseous ammonia. The gaseous ammonia rea...
|
|
WO/2020/201326A1 |
The present invention relates to novel aminoguanidine hydrazone-derivatives of Formula (I) which are effective as retromer stabilizers and useful as neuroprotecting drugs. The invention also relates to pharmaceutical compositions compris...
|
|
WO/2020/202072A1 |
The present invention relates to a compound of Formula la, lb and Ic, (Formula Ia) a pharmaceutical composition comprising the same and their use in the treatment or prevention of pathological conditions associated to depolarizing GABAer...
|
|
WO/2020/199757A1 |
The present invention relates to a sulfonylbenzamide derivative, a preparation method therefor, and a medical use thereof. Specifically, disclosed are a compound of formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvat...
|
|
WO/2020/205789A1 |
Electrolytes and polymers for a lithium battery can include a fluorinated aryl sulfonimide salt or fluorinated aryl sulfonimide polymer.
|
|
WO/2020/205470A1 |
The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
|
|
WO/2020/204041A1 |
Provided is a colored dispersion that contains (A) a dye derivative, (B) a water-insoluble dye, (C) a dispersant, and water, wherein the (A) component contains an anthraquinone-based compound represented by formula (a1), the (C) componen...
|
|
WO/2020/194272A1 |
The present application relates to fluorinated benzylsulfonamide hydroxamic acid compounds of Formula I and/or pharmaceutically acceptable salt, solvate and/or prodrug thereof : (I) for use as a inhibitor of HDAC6. The application also r...
|
|
WO/2020/193419A1 |
The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.
|
|
WO/2020/193322A1 |
The present invention relates to compounds of Formula (I), wherein R1 and R2 are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula ...
|
|
WO/2020/184336A1 |
Provided is a liquid metal complex having oxygen-absorbing ability and containing: a cobalt acacene complex or a derivative thereof; and an ionic liquid in which an ionic ligand having an amine structure and a counter ion thereof are pai...
|
|
WO/2020/176686A1 |
The present invention concerns novel methods of treatment for venetoclax-resistant acute myeloid leukemia, particularly in subjects with a low expression of TP53 protein or expression of TP53 protein associated with a mutation of the TP5...
|
|
WO/2020/175495A1 |
Provided is a method for producing a salt by reacting M+X- with YH so as to generate XH and M+Y-, and then removing the generated XH so as to obtain M+Y-. M+X- is a salt of a cation represented by M+ and an anion represented by X-. M+Y- ...
|
|
WO/2020/168290A1 |
Provided herein are methods for treating a disease, such as cancer, the methods including administering one or more N-aryl benezenesulfonamides or analogs thereof to a subject in need thereof.
|
|
WO/2020/157771A1 |
The present invention relates to preparation of pyrazoles. This invention further relates to a continuous flow micro-total process system for preparation of celecoxib, a COX-2 selective non-steroidal anti-inflammatory drug, and analogs t...
|
|
WO/2020/157126A1 |
The present invention relates to a class of novel compounds of general formula (I), their use as medicaments and pharmaceutical compositions comprising them. Specifically, the compounds of the invention are useful as voltage-gated potass...
|
|
WO/2020/160140A1 |
Disclosed in certain embodiments is a method of treating a pulmonary disease comprising administering a therapeutically effective amount of a Matrix Metalloproteinase (MMP) Inhibitor to a patient in need thereof wherein the pulmonary dis...
|
|
WO/2020/154499A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/154321A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula (AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/151799A1 |
The present invention relates to improved (simplified/easier, more robust and more reproducible) methods for identification of carbohydrates compositions, e.g. out of complex carbohydrate mixtures, as well as the determination of carbohy...
|
|
WO/2020/151804A1 |
Sulfonated 2(7)-aminoacridone and 1-aminopyrene dyes and their use as fluorescent tags, in particular for carbohydrate analysis The invention relates to fluorescent dyes with multiple negatively charged groups in their ionized form which...
|
|
WO/2020/154214A1 |
Provided herein is a method of administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is being administered an organic anion transporter-1 (OAT1) inhibitor and/or ...
|
|
WO/2020/148619A1 |
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...
|
|
WO/2020/148760A1 |
The invention generally concerns a novel class of CB 1 receptor binding molecules and uses thereof.
|
|
WO/2020/146274A1 |
The present technology is directed to fluorinated alkylsulfonamide electrolyte salts with high solubility, conductivity, and electrochemical stability as well as batteries incorporating fluorinated alkylsulfonamide salts. In any aspect a...
|
|
WO/2020/142809A1 |
A method and an angioplasty balloon catheter used in a method of preventing or minimizing incidence of neointimal hyperplasia (NIH) in a blood vessel of an animal following angioplasty treatment. The method comprising locating the angiop...
|
|
WO/2020/127960A1 |
The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
|
|
WO/2020/124262A1 |
The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a cell proliferative disorder such as a cancer using a compound of formula (I) ...
|
|
WO/2020/127675A1 |
Described are colour developers of formula (I) Ar1-SO2-NH-C6H4-SO2-C6H4-NH-CO-NH-Ar2 (I), a heat-sensitive recording material, comprising a base substrate and also a heat-sensitive, colour-forming layer comprising at least one colour for...
|
|
WO/2020/115419A1 |
The invention relates to a process for producing a compound having the following formula (III): R2-(SO2)-NLi-(SO2)-F (III) wherein said process comprises: - a step b) which comprises: - a step b1) of fluorinating a compound having the fo...
|
|
WO/2020/112934A1 |
Provided herein are methods for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) substrate t...
|
|
WO/2020/112935A1 |
Provided herein is a method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a therapeutically effective amount of a drug chos...
|
|
WO/2020/112672A1 |
The present invention is based in part on the identification of biomarkers, including NQOl, NRF2 and KEAP1, predictive of cancer cell responsiveness to treatment with ML 329 or a derivative thereof.
|
|
WO/2020/109720A1 |
The invention relates to a process for producing lithium bis(fluorosulfonyl)imide salt. The present invention discloses a process for producing lithium bis(fluorosulfonyl)imide salt involving the following steps: a) a step of producing b...
|
|
WO/2020/104634A1 |
This invention relates to compounds of general formula: wherein R0A and R0B are independently selected from hydrogen and pharmaceutically acceptable cations; and RA and RB are identical and selected from amide, carbamate, sulphonamide, a...
|
|
WO/2020/102901A1 |
Provided herein are synthetic compounds useful for inhibiting bacterial growth and uses thereof. Also provided are pharmaceutical compositions. The compounds and pharmaceutical compositions are useful for inhibiting growth of a bacterium...
|
